Come together to increase awareness, provide help for today and hope for tomorrow for millions living with alopecia areata.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for the treatment of multiple dermatologic indications ...

Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an interleukin-2 receptor pathway agonist that has shown success in other autoimmune ...

Targeting follicular stem cells with a topical mitochondrial pyruvate carrier inhibitor induces rapid hair density gains in ...

At about 26 years old, my father became sick and lost all of his hair. Not only did he lose hair on his head, he had no eyebrows, eyelashes or beard and even lost the hair on his arms and legs. Do you ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...